A phase II clinical trial with HLH-94 protocol, etoposide plus corticosteroid combination therapy, for severe illness patients with COVID-19
- Funded by Japan Agency for Medical Research and Development (AMED)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Funder
Japan Agency for Medical Research and Development (AMED)Principal Investigator
Associate Professor Tetsuji AOYAGIResearch Location
JapanLead Research Institution
Internal Medicine, Department of Infectious Diseases, Tohoku UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Phase 2 clinical trialSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Clinical Trial, Phase IIBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified